PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
24 avr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
19 avr. 2018 06h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...
Streetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double'
15 nov. 2017 09h00 HE
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. Included in this article...
Biopsy Devices Market size to exceed $3bn by 2024: Global Market Insights Inc.
29 août 2016 10h00 HE
|
Global Market Insights
Ocean View, Delaware, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Biopsy Devices Market size is estimated to see USD 3.1 billion revenues by 2024; as reported by Global Market Insights, Inc. Growing...
Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
11 nov. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
HEPREGEN ANNOUNCES PUBLICATION OF SEVERAL SCIENTIFIC PAPERS PROVIDING EVIDENCE OF THE UNPRECEDENTED UTILITY OF ITS HEPATOPACTM PRODUCTS
12 févr. 2014 12h26 HE
|
Hepregen
MEDFORD, Mass., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Hepregen Corporation, leader in the development of next generation HepatoPacTM and HepatoMuneTM cell-based in vitro assay products, announced today...
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
13 janv. 2014 07h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
Methuselah Foundation Announces $1 Million "New Organ Liver Prize" at World Stem Cell Summit
05 déc. 2013 11h47 HE
|
Genetics Policy Institute
SAN DIEGO, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Methuselah Foundation, a medical charity based in Springfield, VA, announced today at the World Stem Cell Summit in San Diego the official launch of the $1...
American Heart Association Comment: FDA Announces Safety Changes on Labeling for Some Statins
28 févr. 2012 18h03 HE
|
American Heart Association
DALLAS, Feb. 28, 2012 (GLOBE NEWSWIRE) -- The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering...